 | • レポートコード：MRC2108A158 • 出版社/出版日：Mordor Intelligence / 2021年7月26日 • レポート形態：英文、PDF、153ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、2020年に6,697.08百万ドルであった経腸栄養剤の世界市場規模が、2021年から2026年の間に年平均7％成長し、2026年までに10,069.30百万ドルに達すると予測しています。本調査レポートは、世界の経腸栄養剤市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（標準栄養剤、疾患特有栄養剤）分析、用途別（腫瘍、神経疾患、救急治療、糖尿病、消化器疾患）分析、エンドユーザー別（病院、在宅医療＆ホスピス、その他）分析、流通チャネル別（病院、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・経腸栄養剤の世界市場規模：製品別（標準栄養剤、疾患特有栄養剤） ・経腸栄養剤の世界市場規模：用途別（腫瘍、神経疾患、救急治療、糖尿病、消化器疾患） ・経腸栄養剤の世界市場規模：エンドユーザー別（病院、在宅医療＆ホスピス、その他） ・経腸栄養剤の世界市場規模：流通チャネル別（病院、小売薬局、オンライン薬局） ・経腸栄養剤の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Abbott Laboratories、B. Braun Melsungen AG、Danone SA (Nutricia)、Fresenius SE & Co. KgaA (Fresenius Kabi AG)、Global Health Product Inc.、Reckitt Benckiser Group plc. (Mead Johnson)、Meiji Holdings Co. Ltd、Nestle SA、Trovita Health Science、Victus Inc.） ・市場機会/将来の見通し |
The global enteral feeding formulas market was valued at USD 6,697.08 million in 2020, and it is expected to reach USD 10,069.30 million by 2026, registering a CAGR of 7%, during the forecast period.
The outbreak of COVID-19 is expected to impact the enteral feeding formulas market, as good supportive care remains the cornerstone in managing critically ill patients with COVID-19 infection, within which nutritional management of the ICU admitted COVID-19 patients is an integral component of the supportive measures. According to the research article published in the Society of Critical Care Medicine and the American Society for Parenteral and Enteral Nutrition, 2020, initiating early enteral nutrition (EN) within 24-36 hours of admission to the ICU or within 12 hours of intubation and placement on mechanical ventilation is recommended in the treatment of COVID-19 patients. The publication also suggested that enteral nutrition be preferred over parenteral nutrition.
The enteral feeding formulas market is largely driven by increasing prevalence of metabolic and chronic disorder, increase expenditure on patient care and growing geriatric population. According to the World Heart Federation 2018, coronary heart disease is the leading cause of death worldwide. An estimated 3.8 million men and 3.4 million women die each year from coronary heart disease. In addition, 80% of the deaths occur in low- and middle-income countries. Moreover, rise in the number of premature births, growing nutritional deficiencies, such as severe deficiency of protein and other micronutrients in infants and pregnant women population will drive the demand for nutritional requirement, which ultimately boost the overall market growth.
Also, ageing is the major factor that is driving the market growth for the treatment. According to the United nations department of Economics and Social 2019 report, it was estimated that by the year 2050, one in six people around the world will be over age 65 years old (16%), up from 1 in 11 in the year 2019 (9%). By the year 2050, 1 in 4 persons living in Europe and Northern America could be aged 65 or over that. In the year 2018, for the first time in history, persons aged 65 or above outnumbered children under five years of age globally. The number of persons aged 80 years and above is projected to be the triple, from 143 million in the year 2019 to approximately 426 million in 2050. Also, according to the article published on National Center for Biotechnology Information 2018, the prevalence of nutrient deficiency in the geriatric population is around 15% in ambulatory outpatients and 35%-65% among hospitalized patients. Thus, the demand for enteral nutrition will rise with the growing geriatric population. Furthermore, the rising healthcare expenditure in developed and developing countries and the increasing demand for home healthcare services will also boost the enteral feeding formulas market growth.
Key Market Trends
Oncology Segment is Expected to Hold a Major Market Share in the Enteral Feeding Formulas Market
The majority of cancer patients suffer from cancer cachexia, which causes insulin resistance, increased lipolysis with loss of body fat, increased protein turnover, and loss of muscle mass, causing loss of appetite and weight.
As per the International Agency for Research on Cancer (IARC) in December 2020, estimated that globally, 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. IARC estimated that in 2020, the prevalence of cancer has risen to 19.3 million cases and 10 million cancer deaths in 2020, which was around 18 million cancer cases around the world in 2018. With this growing burden, the prevention of cancer is one of the most significant challenges. The cancer burden differs by region. Almost half of the cancer prevalence occurs in Asia, and in Europe, one-quarter of the population is suffering from cancer. Furthermore, to improve the clinical condition of cancer patients, providing nutrition is the cornerstone, as it becomes very difficult for cancer patients to take the food orally. As the treatment proceeds, nutrition is supplied by enteral feeding tubes to enable them to maintain the body mass.
Furthermore, the research presented in the 2020 Virtual Congress on Clinical Nutrition and Metabolism, the annual conference of the European Society for Clinical Nutrition and Metabolism (ESPEN), demonstrated that Kate Farms’ plant-based, oral, enteral formulas (PBEF) can help adult oncology patients maintain or gain weight, allowing them to receive the treatment they need. Hence, the increasing incidence and prevalence of cancer may contribute to the growth of the market studied, during the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
North America is expected to dominate the enteral feeding formulas market, because of the factors, such as the rapid aging population, the surging prevalence of preterm birth, and the rise in the number of chronic disease patients. According to the Population Reference Bureau’s Population Bulletin Aging in the United States, the Americans aged 65 and older are projected to nearly double from 52 million in 2018 to 95 million by 2060.
The rise in the geriatric population will increase the cases of chronic diseases, such as cancer and diabetes, which will further lead to an increase in the hospital stay of the patient. According to the GLOBOCON 2020, the new cancer cases diagnosed were 2,281,658 in the United States in 2020, with 612,390 deaths. Among all cancers, breast cancer had the highest incidence with 253,465 cases, followed by lung (227,875), prostate (209,512), and colon (101,809) new cancer cases in 2020 in the United States. According to American Hospital Association, Fast Facts on US Hospitals, 2021, 36,241,815 admissions were reported in US Hospitals in 2019, with a total of USD 1,161,032,419,000 expense. Hence, all of the above-mentioned factors are expected to drive the growth of the market.
Competitive Landscape
The enteral feeding formulas market is moderately consolidated. The key market players include Abbott Laboratories, Nestle SA, Danone SA, Fresenius Kabi AG, B. Braun Melsungen AG, Reckitt Benckiser Group plc. (Mead Johnson), Trovita Health Science, Global Health Product Inc., Meiji Holdings Co. Ltd, and Victus, among others.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Metabolic and Chronic Diseases
4.2.2 Increasing Spending on Patient Care
4.2.3 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Complications Associated with Enteral Nutrition
4.3.2 High Cost and Low Adherence Rates in Developing Countries
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 Standard Formulas
5.1.2 Disease-specific Formulas
5.2 By Application
5.2.1 Oncology
5.2.2 Neurology
5.2.3 Critical Care
5.2.4 Diabetes
5.2.5 Gastroenterology
5.2.6 Other Applications
5.3 By End User
5.3.1 Hospital
5.3.2 Home Care Agencies and Hospices
5.3.3 Other End Users
5.4 By Distributuion Channel
5.4.1 Hospitals
5.4.2 Retail Pharmacies
5.4.3 Online Pharmacies
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 B. Braun Melsungen AG
6.1.3 Danone SA (Nutricia)
6.1.4 Fresenius SE & Co. KgaA (Fresenius Kabi AG)
6.1.5 Global Health Product Inc.
6.1.6 Reckitt Benckiser Group plc. (Mead Johnson)
6.1.7 Meiji Holdings Co. Ltd
6.1.8 Nestle SA
6.1.9 Trovita Health Science
6.1.10 Victus Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS